Loading
A phase 3 trial of Odronextamab, Rituximab, Cyclophosphamide in follicular lymphoma, run by Regeneron Pharmaceuticals, now recruiting.
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma is a phase 3 interventional study registered as NCT06091254 by Regeneron Pharmaceuticals, with 822 participants planned, started 2023-12-12 and due to reach its primary completion in 2028-02-07. Interventions recorded: Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine. Conditions listed: Follicular Lymphoma (FL). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Odronextamab, Regeneron, Prednisone, Vincristine.
Shares Odronextamab, Regeneron, Prednisone, Vincristine.
Shares Odronextamab, Regeneron, Rituximab, T-cell engagers (bispecific).
Shares Prednisone, Vincristine, Rituximab, T-cell engagers (bispecific).
Shares Prednisone, Vincristine, Rituximab, Follicular lymphoma.
Shares Prednisone, Vincristine, Rituximab, T-cell engagers (bispecific).
Shares Prednisone, Vincristine, Rituximab, T-cell engagers (bispecific).
Shares Prednisone, Vincristine, Rituximab, Doxorubicin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/